nct_id: NCT06219941
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2024-01-23'
study_start_date: '2023-12-13'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: l-leucovorin'
  - drug_name: 'Drug: Irinotecan'
  - drug_name: 'Drug: 5-Fluorouracil'
  - drug_name: 'Drug: Leucovorin'
  - drug_name: 'Drug: Gemcitabine'
  - drug_name: 'Drug: AZD0901'
  - drug_name: 'Drug: Nanoliposomal Irinotecan'
long_title: A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability,
  Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With
  Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin
  18.2 (CLARITY-PanTumour01)
last_updated: '2025-09-02'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE2
principal_investigator: NA
principal_investigator_institution: AstraZeneca
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 190
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- The list below is a summarised eligibility criteria for the study - refer to the
  study protocol for full criteria.
- 'Master Inclusion Criteria applicable to all sub studies:'
- "* Participant must be \u2265 18 years or the legal age of consent at the time of\
  \ signing the ICF."
- '* Participants who are CLDN18.2 positive.'
- '* Must have at least one measurable lesion according to RECIST v1.1.'
- '* ECOG performance status of 0 to 1 with no deterioration over the previous 2 weeks
  prior first day of dosing.'
- "* Predicted life expectancy of \u2265 12 weeks."
- '* Adequate organ and bone marrow function as defined by protocol.'
- '* Body weight \> 35 kg.'
- '* Participants are willing to comply with contraception requirements.'
- 'Sub study 1 Specific Inclusion criteria:'
- '* Histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction.'
- '* Advanced or metastatic GC/GEJC.'
- '* Maximum 2 prior lines of systemic treatment for unresectable or metastatic disease.'
- 'Sub study 2 Specific Inclusion criteria:'
- '* Participants diagnosed with histologically confirmed metastatic or advanced PDAC.'
- '* Availability of an archival sample or a fresh tumour biopsy taken at screening.'
- "* No prior treatments for unresectable or metastatic disease. Prior neoadjuvant/adjuvant\
  \ chemotherapy is permitted as long as participants progressed \u2265 6 months (183\
  \ days) from the last dose."
- Sub study 3 Specific Inclusion criteria
- '* Histologically confirmed, unresectable advanced, or metastatic adenocarcinoma
  of biliary tract, including cholangiocarcinoma (intrahepatic or extrahepatic) and
  gallbladder carcinoma (NOTE: Ampullary cancers are not eligible).'
- '* Documented radiographic or clinical disease progression on or after at least
  one prior regimen and maximum 2 prior lines of systemic treatment for unresectable
  or metastatic disease.'
- 'Exclude - Master Exclusion Criteria applicable to all sub studies:'
- Exclude - * Unstable or active peptic ulcer disease or digestive tract bleeding
  including but not limited to clinically significant bleeding in the setting of prior
  CLDN18.2 directed therapy.
- Exclude - * Participants with clinically significant ascites that require drainage.
- Exclude - * A history of drug-induced non-infectious ILD/pneumonitis.
- Exclude - * Central nervous system metastases or CNS pathology.
- "Exclude - * Peripheral neuropathy, sensory, or motor \u2265 Grade 2 at screening."
- Exclude - * History of another primary malignancy.
- Exclude - * Prior exposure to any MMAE-based ADC.
- Exclude - * Prior exposure to any CLDN18.2 targeted agents except anti-CLDN18.2
  monoclonal antibody.
- 'Exclude - Sub study 1 Specific Exclusion criteria:'
- Exclude - * Participants with HER2-positive (3+ by IHC, or 2+ by IHC, and positive
  by ISH) or indeterminate GC/GEJC unless they have failed/not tolerated/or are not
  eligible for standard anti-HER2 therapy, where available.
- Exclude - * Any factors that increase the risk of QTc prolongation or risk of arrhythmic
  events.
- Exclude - * The use of concomitant medications known to prolong the QT/QTc interval.
- 'Exclude - Sub study 2 Specific Exclusion criteria:'
- Exclude - * Known DPD enzyme deficiency based on local testing where testing is
  SoC.
- Exclude - * Use of strong inhibitor or inducer of UGT1A1.
- Exclude - * Use of strong inhibitors or inducers of CYP3A4.
- Exclude - * Known homozygous for the UGT1A1\*28 allele based on local testing where
  testing is SoC.
- Exclude - Sub study 3 Specific Exclusion criteria
- "Exclude - \u2022 Clinically significant biliary obstruction that has not resolved\
  \ before enrollment."
short_title: AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: AstraZeneca
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: The purpose of this study is to assess the safety, tolerability, efficacy,
  pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination
  with anti-cancer agents in participants with locally advanced unresectable or metastatic
  solid tumours expressing CLDN18.2.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Sub Study 1 - AZD0901 MONOTHERAPY
      arm_internal_id: 0
      arm_description: Sub Study 1 will investigate AZD0901 monotherapy in order to
        evaluate the safety, tolerability, and efficacy of AZD0901.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: AZD0901'
        level_internal_id: 0
        level_suspended: N
    - arm_code: Sub Study 2 - AZD0901 IN COMBINATION WITH ANTI-CANCER AGENTS IN PANCREATIC
        DUCTAL ADENOCARCINOMA
      arm_internal_id: 1
      arm_description: Substudy 2 will investigate the safety and efficacy of AZD0901
        as first line systemic treatment used in combination with different chemotherapy
        agents
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: AZD0901'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: 5-Fluorouracil'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Leucovorin'
        level_internal_id: 2
        level_suspended: N
      - level_code: '3'
        level_description: 'Drug: l-leucovorin'
        level_internal_id: 3
        level_suspended: N
      - level_code: '4'
        level_description: 'Drug: Irinotecan'
        level_internal_id: 4
        level_suspended: N
      - level_code: '5'
        level_description: 'Drug: Nanoliposomal Irinotecan'
        level_internal_id: 5
        level_suspended: N
      - level_code: '6'
        level_description: 'Drug: Gemcitabine'
        level_internal_id: 6
        level_suspended: N
    - arm_code: 'Sub Study 3: AZD0901 MONOTHERAPY IN BILIARY TRACT CANCER'
      arm_internal_id: 2
      arm_description: Substudy 3 Further evaluate the preliminary anti-tumour activity
        of AZD0901 monotherapy by assessment of DRR.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: AZD0901'
        level_internal_id: 0
        level_suspended: N
    match:
    - and:
      - or:
        - clinical:
            oncotree_primary_diagnosis: Intraductal Papillary Neoplasm of the Bile
              Duct
        - clinical:
            oncotree_primary_diagnosis: Esophageal Squamous Cell Carcinoma
        - clinical:
            oncotree_primary_diagnosis: Intracholecystic Papillary Neoplasm
        - clinical:
            oncotree_primary_diagnosis: Pancreatic Adenocarcinoma
        - clinical:
            oncotree_primary_diagnosis: Esophagogastric Adenocarcinoma
      - clinical:
          age_numerical: '>=18'
          her2_status: Positive
          disease_status:
          - Advanced
          - Metastatic
          - Unresectable
